{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:02:26Z","timestamp":1790510546730,"version":"4.1.0"},"reference-count":66,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2020.4987","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T06:55:52Z","timestamp":1581663352000},"source":"Crossref","is-referenced-by-count":11,"title":["Although c\u2011MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER\u2011positive breast cancer"],"prefix":"10.3892","author":[{"given":"Rui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The People's Hospital of Deyang, Deyang, Sichuan 618000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beige","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manran","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"key20200713190313_b1-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"key20200713190313_b2-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/jnci\/djr257","article-title":"Incidence of breast cancer in the United States: Current and future trends","volume":"103","author":"Anderson","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key20200713190313_b3-ijo-56-04-0932","first-page":"1454","article-title":"Breast cancer","volume":"343","author":"Marshall","year":"2014","journal-title":"Dare to do less Science"},{"key":"key20200713190313_b4-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrc2193","article-title":"Modelling breast cancer: One size does not fit all","volume":"7","author":"Vargo-Gogola","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20200713190313_b5-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrc2211","article-title":"Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state","volume":"7","author":"Green","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20200713190313_b6-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key20200713190313_b7-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.mce.2013.09.038","article-title":"Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer","volume":"382","author":"Patani","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"key20200713190313_b8-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20200713190313_b9-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/ERC-14-0092","article-title":"Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer","volume":"21","author":"Jordan","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"key20200713190313_b10-ijo-56-04-0932","first-page":"185","article-title":"Tamoxifen metabolism and its effect on endocrine treatment of breast cancer","volume":"7","author":"Briest","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20200713190313_b11-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.hoc.2007.03.002","article-title":"Adjuvant endocrine treatment of early breast cancer","volume":"21","author":"L\u00f8nning","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20200713190313_b12-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group","year":"2008","journal-title":"Lancet Oncol"},{"key":"key20200713190313_b13-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2217\/epi.11.72","article-title":"Epigenetic modulation: A novel therapeutic target for overcoming hormonal therapy resistance","volume":"3","author":"Raha","year":"2011","journal-title":"Epigenomics"},{"key":"key20200713190313_b14-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/0008-5472.CAN-14-0652","article-title":"Reprogramming of the ERRalpha and ERalpha target gene landscape triggers tamoxifen resistance in breast cancer","volume":"75","author":"Thewes","year":"2015","journal-title":"Cancer Res"},{"key":"key20200713190313_b15-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/sj.bjc.6605627","article-title":"Tamoxifen resistance in early breast cancer: Statistical modelling of tissue markers to improve risk prediction","volume":"102","author":"Baneshi","year":"2010","journal-title":"Br J Cancer"},{"key":"key20200713190313_b16-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"key20200713190313_b17-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713190313_b18-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.breast.2015.02.031","article-title":"Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal","volume":"24","author":"Zagouri","year":"2015","journal-title":"Breast"},{"key":"key20200713190313_b19-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13058-015-0579-y","article-title":"Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: A new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and \u03b21-integrin signaling pathway in tumor cells","volume":"17","author":"Yuan","year":"2015","journal-title":"Breast Cancer Res"},{"key":"key20200713190313_b20-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2017.01.014","article-title":"Essential role of Notch4\/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer","volume":"390","author":"Bui","year":"2017","journal-title":"Cancer Lett"},{"key":"key20200713190313_b21-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/onc.2012.128","article-title":"Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer","volume":"32","author":"Ward","year":"2013","journal-title":"Oncogene"},{"key":"key20200713190313_b22-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"key20200713190313_b23-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.3390\/biom7030053","article-title":"MYC-driven pathways in breast cancer subtypes","volume":"7","author":"Fallah","year":"2017","journal-title":"Biomolecules"},{"key":"key20200713190313_b24-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13058-015-0533-z","article-title":"Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression","volume":"17","author":"Raha","year":"2015","journal-title":"Breast Cancer Res"},{"key":"key20200713190313_b25-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"29300","DOI":"10.18632\/oncotarget.16832","article-title":"Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damages","volume":"8","author":"Qi","year":"2017","journal-title":"Oncotarget"},{"key":"key20200713190313_b26-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm Stat"},{"key":"key20200713190313_b27-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713190313_b28-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20200713190313_b29-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10549-015-3418-z","article-title":"Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: A retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy","volume":"151","author":"Yuan","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"key20200713190313_b30-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"13525","DOI":"10.1038\/ncomms13525","article-title":"Amplification of USP13 drives ovarian cancer metabolism","volume":"7","author":"Han","year":"2016","journal-title":"Nat Commun"},{"key":"key20200713190313_b31-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"Lindstr\u00f6m","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20200713190313_b32-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.1158\/0008-5472.CAN-12-1305","article-title":"Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells","volume":"72","author":"Cui","year":"2012","journal-title":"Cancer Res"},{"key":"key20200713190313_b33-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1073\/pnas.1018157108","article-title":"High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy","volume":"108","author":"Gonzalez-Malerva","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713190313_b34-ijo-56-04-0932","doi-asserted-by":"crossref","first-page":"30252","DOI":"10.18632\/oncotarget.16325","article-title":"Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"key20200713190313_b35-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2005.12.016","article-title":"Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters","volume":"21","author":"Cheng","year":"2006","journal-title":"Mol Cell"},{"key":"key20200713190313_b36-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"e2987","DOI":"10.1371\/journal.pone.0002987","article-title":"Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer","volume":"3","author":"Musgrove","year":"2008","journal-title":"PLoS One"},{"key":"key20200713190313_b37-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187152007779314044","article-title":"Biochemical mechanisms of cisplatin cytotoxicity","volume":"7","author":"Cepeda","year":"2007","journal-title":"Anticancer Agents Med Chem"},{"key":"key20200713190313_b38-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrd4553","article-title":"Exploiting replicative stress to treat cancer","volume":"14","author":"Dobbelstein","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713190313_b39-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"key20200713190313_b40-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ccell.2018.03.006","article-title":"lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer","volume":"33","author":"Wang","year":"2018","journal-title":"Cancer Cell"},{"key":"key20200713190313_b41-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20200713190313_b42-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.02.004","article-title":"Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials","volume":"45","author":"Graham","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"key20200713190313_b43-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"key20200713190313_b44-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"key20200713190313_b45-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2008.17.1462","article-title":"Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance","volume":"27","author":"van Agthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20200713190313_b46-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1093\/annonc\/mdx036","article-title":"3rd ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"key20200713190313_b47-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713190313_b48-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"key20200713190313_b49-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"key20200713190313_b50-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-15-0090","article-title":"HOXB7 is an ER\u03b1 cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance","volume":"5","author":"Jin","year":"2015","journal-title":"Cancer Discov"},{"key":"key20200713190313_b51-ijo-56-04-0932","first-page":"e0155840","article-title":"Analysis of paired primary-metastatic hormone-receptor positive breast tumors (HRPBC) uncovers potential novel drivers of hormonal resistance","volume-title":"PLoS One","author":"Manso","year":"2016"},{"key":"key20200713190313_b52-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1158\/1078-0432.CCR-10-2567","article-title":"A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance","volume":"17","author":"Miller","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20200713190313_b53-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3892\/or.2015.3721","article-title":"Anti-estrogenresistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment","volume":"33","author":"Yin","year":"2015","journal-title":"Oncol Rep"},{"key":"key20200713190313_b54-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1158\/1535-7163.MCT-07-0072","article-title":"Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death","volume":"6","author":"Yde","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20200713190313_b55-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2014.00221","article-title":"Hormone resistance in Two MCF-7 breast cancer cell lines is associated with reduced mTOR signaling, decreased glycolysis, and increased sensitivity to cytotoxic drugs","volume":"4","author":"Leung","year":"2014","journal-title":"Front Oncol"},{"key":"key20200713190313_b56-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"30788","DOI":"10.1038\/srep30788","article-title":"PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci Rep"},{"key":"key20200713190313_b57-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"key20200713190313_b58-ijo-56-04-0932","first-page":"e91771","article-title":"CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance","volume-title":"PLoS One","author":"Gao","year":"2014"},{"key":"key20200713190313_b59-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1038\/s41467-018-06309-8","article-title":"LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4\/6-Rb and ER\u03b1 pathway","volume":"9","author":"Gao","year":"2018","journal-title":"Nat Commun"},{"key":"key20200713190313_b60-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12885-016-2452-5","article-title":"Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer","volume":"16","author":"Kangaspeska","year":"2016","journal-title":"BMC Cancer"},{"key":"key20200713190313_b61-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.canlet.2013.02.059","article-title":"Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells","volume":"335","author":"Jiang","year":"2013","journal-title":"Cancer Lett"},{"key":"key20200713190313_b62-ijo-56-04-0932","first-page":"1061","article-title":"P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer","volume":"20","author":"Baekelandt","year":"2000","journal-title":"Anticancer Res"},{"key":"key20200713190313_b63-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0301-472X(98)00027-7","article-title":"Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells","volume":"27","author":"Wada","year":"1999","journal-title":"Exp Hematol"},{"key":"key20200713190313_b64-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/andr.299","article-title":"Cisplatin resistance in germ cell tumours: Models and mechanisms","volume":"3","author":"Jacobsen","year":"2015","journal-title":"Andrology"},{"key":"key20200713190313_b65-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"key":"key20200713190313_b66-ijo-56-04-0932","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/s41467-018-03951-0","article-title":"Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat Commun"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:07:55Z","timestamp":1594667275000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2020.4987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":66,"URL":"https:\/\/doi.org\/10.3892\/ijo.2020.4987","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}